Olympus $500 million senior notes offering
The debut offering consisted of 2.143% senior notes due 2026
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Privia Health $174 million secondary offering
We advised Privia on its SEC-registered offering of stock
Alignment Healthcare $193 million SEC-registered secondary offering
The shares are listed on the Nasdaq Global Select Market
Apria $141.7 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Revolution Medicines $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Affimed $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Cryoport $403 million notes offering and concurrent $249 million stock offering
The company issued 0.75% convertible senior notes due 2026 and sold shares in a registered direct offering
Aligos Therapeutics $75 million at-the-market offering
The company issued common stock in the SEC-registered at-the-market offering
Option Care Health $500 million notes offering
The company issued high-yield senior notes due 2029 in the Rule 144A / Regulation S offering
IVERIC bio $173.4 million stock offering
We advised the underwriters on the SEC-registered equity offering